# A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases

> **NCT04948099** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 73 (actual)

## Conditions studied

- Dendritic Cell -Mediated Rheumatic Diseases

## Interventions

- **DRUG:** VIB1116
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04948099
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-06
- **Primary completion:** 2023-07-03
- **Final completion:** 2023-07-03
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04948099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04948099, "A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04948099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*